Based on our ANDA filing date and the approval timeline, NATCO believes that we are eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product
at the time of launch.
As per industry sales data, IMBRUVICA (Tablet and Capsule dosage forms) had generated annual sales of
strengths of IMBRUVICA Tablets alone generated sales of
Contact:
Registered Office and
Corporate Headquarters
Natco House
Road No.2,
T: +91-40-2354 7532
T: +91-40-2354 5298/23548243
Website: www.natcopharma.com
(C) 2021 Electronic News Publishing, source